Trial Profile

A Phase 1 Study to Evaluate the Efficacy and Safety of AB-101, an Allogeneic Cord Blood- Derived NK-Cell Therapy in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 17 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AB 101 Artiva Biotherapeutics (Primary) ; Obinutuzumab (Primary) ; Rituximab (Primary) ; Cyclophosphamide; Fludarabine
Indications Lupus nephritis
Focus Adverse reactions; Therapeutic Use
Sponsors Atriva Therapeutics

11 Jun 2025 Planned End Date changed from 1 Oct 2026 to 1 Aug 2027.
11 Jun 2025 Planned primary completion date changed from 1 Oct 2026 to 1 Aug 2027.
29 Aug 2024 According to an Artiva Biotherapeutics media release, the company expect to report initial data on autoimmune indications from at least one of the Phase 1/1b trial or the basket IIT in the first half of 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com